Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 12/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894184 | 0.84 | TRPA1 (0.63) | TRPA1 | |
| SCHEMBL893949 | 0.83 | TRPA1 (0.47) | TRPA1CHRM3CFDCCR1 | |
| SCHEMBL893649 | 0.83 | TRPA1 (0.43) | TRPA1CHRM3CFDEPHX2LMNA | |
| SCHEMBL17136512 | 0.74 | TRPA1 (0.54) | TRPA1EPHX2ALDH1A1 | |
| SCHEMBL13044948 | 0.74 | TACR1 (0.44) | TRPA1CHRM3CFDATM | |
| SCHEMBL17136509 | 0.73 | TRPA1 (0.59) | TRPA1ALDH1A1 | |
| SCHEMBL17199902 | 0.73 | TRPA1 (0.58) | TRPA1ALDH1A1 | |
| SCHEMBL17199887 | 0.72 | TRPA1 (0.56) | TRPA1ALDH1A1 | |
| SCHEMBL892880 | 0.72 | TRPA1 (0.57) | TRPA1ALDH1A1 | |
| SCHEMBL892725 | 0.71 | TRPA1 (0.58) | TRPA1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | claimed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885CHRM3 279/4885CFD 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.